MedTrace Logo

Fasenra: An Asthma Study

NCT07654842 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-07

No results posted yet for this study

Summary

The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.

Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.

Conditions

Interventions

DRUG

Budesonide-albuterol

Budesonide-albuterol will be used as an anti-inflammatory reliever inhaler for the duration of the study.

DRUG

Benralizumab

Participants will continue using benralizumab as prescribed. Benralizumab is not supplied by the study.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Endeavor Health

    lead OTHER

Principal Investigators

  • Giselle Mosnaim, MD, MS · Endeavor Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-09-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07654842 on ClinicalTrials.gov